Table 3 Re-extracted information on initial mean weight, final weight, and mean weight change
Initial Weight (kg) | Final Weight (kg) | Mean Weight Change (kg) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Study | Year | Groups | Mean | SD | Mean | Mean | SE | SD | N a |
Apovian [9] | 2013 | Placebo | 99.2 | 15.9 | 97.7 | -1.5 | 0.5 | 8.17 | 267 |
32 mg/ day naltrexone SR + 360 mg/day bupropion SR (NB32) | 100.3 | 16.6 | 92.4 | -7.9 | 0.3 | 6.25 | 434 | ||
Aronne [10] | 2010 | Placebo | 107 | 22 | 104.9 | -2.1 | 0.9 | 6.85 | 58 |
Pramlintide (120 µg sc) | 102 | 19 | 98.4 | -3.6 | 0.7 | 5.33 | 58 | ||
*Pramlintide (120 µg sc t.i.d.) + sibutramine (10 mg oral q.a.m.) | 101 (NA) | 16 (NA) | 89.7 (NA) | -11.3 (NA) | 1.2 (NA) | 9.06 (NA) | 57 | ||
*Pramlintide (120 µg sc t.i.d.) + phentermine (37.5 mg oral q.a.m.) | 102 (NA) | 18 (NA) | 90.7 (NA) | -11.3 (NA) | 0.9 (NA) | 6.91 (NA) | 59 | ||
Davies [7] | 2015 | *Placebo | 106.5 | 21.3 | 101.3 (104.3) | -5.2 (-2.2) | 1.44 (NA) | 20.86 (NA) | 211 |
*Liraglutide 3.0 mg | 105.7 | 21.9 | 98.2 (99.3) | -7.5 (-6.4) | 1.04 (NA) | 21.13 (NA) | 412 | ||
*Liraglutide 1.8 mg | 105.8 | 21 | 99.8 (100.8) | -6 (-5) | 1.47 (NA) | 21.05 (NA) | 204 | ||
Fidler [11] | 2011 | Placebo | 100.8 | 16.2 | 97.9 | -2.9 | 0.163 (NA) | 6.4 | 1541 |
Lorcaserin 10 mg BID | 100.3 | 15.7 | 94.5 | -5.8 | 0.162 (NA) | 6.4 | 1561 | ||
Lorcaserin 10 mg QD | 100.1 | 16.7 | 95.4 | -4.7 | 0.23 (NA) | 6.4 | 771 | ||
Gadde [12] | 2011 | Placebo | 103.3 | 18.1 | 101.9 | -1.4 | 0.36 (NA) | 11.2 (NA) | 979 |
Phentermine 7.5 mg + topiramate 46.0 mg | 102.6 | 18.2 | 94.5 | -8.1 | 0.51 (NA) | 11.3 (NA) | 488 | ||
*Phentermine 15.0 mg + topiramate 92.0 mg | 103.3 (103) | 17.6 | 93.1 (92.8) | -10.2 | 0.46 (NA) | 14.4 (NA) | 981 | ||
Greenway [8] | 2010 | Placebo | 99.5 | 14.3 | 97.6 | -1.9 | 0.5 | 8.5 (NA) | 290 |
Naltrexone16.0 mg + bupropion | 99.5 | 14.8 | 93 | -6.5 | 0.5 | 8.4 (NA) | 284 | ||
Naltrexone32.0 mg + bupropion | 99.7 | 15.9 | 91.7 | -8 | 0.5 | 8.6 (NA) | 296 | ||
Le Roux [13] | 2017 | Placebo | 107.9 | 21.8 | 105.9 | -2 | 0.27 (NA) | 7.3 | 738 |
Liraglutide 3.0 mg | 107.5 | 21.6 | 101 | -6.5 | 0.21 (NA) | 8.1 | 1472 | ||
Lu [14] | 2018 | Placebo | 91.5 | 14.5 | 87.9 | -3.6 | 0.65 (NA) | 5.87 (NA) | 82 |
Lorcaserin 10.0 mg | 92.6 | 13.3 | 86.8 | -5.8 | 0.56 (NA) | 5.14 (NA) | 84 | ||
O’Neil [15] | 2012 | *Placebo | 101.6 | 18.1 | 99.7 (101.7) | -1.9 (NA) | 0.5 (NA) | 6.26 (NA) | 157 |
*Lorcaserin 10 mg BID | 104.7 | 17.9 | 99.1 (104.7) | -5.6 (NA) | 0.5 (NA) | 6.50 (NA) | 169 | ||
*Lorcaserin 10 mg QD | 105.4 (105.9) | 19 | 99.5 (105.4) | -5.9 (NA) | 0.7 (NA) | 6.06 (NA) | 75 | ||
Pi-Sunyer [16] | 2015 | Placebo | 106.2 | 21.7 | 103.4 | -2.8 | 0.19 (NA) | 6.5 | 1225 |
Liraglutide 3.0 mg QD | 106.2 | 21.2 | 97.8 | -8.4 | 0.15 (NA) | 7.3 | 2437 | ||
Smith [17] | 2010 | Placebo | 99.7 | 15.93 (0.4) | 97.5 | -2.2 | 0.1 | 3.87 (NA) | 1499 |
Lorcaserin 10.0 mg | 100.4 | 15.97 (0.4) | 94.6 | -5.8 | 0.2 | 7.84 (NA) | 1538 | ||